Abstract 14038: Impact of Total Stent Length After Sirolimus-Eluting Stent Implantation on 10-Year Clinical Outcomes
Introduction: We sought to assess the relationship between total stent length (TSL) and long-term clinical outcomes after sirolimus-eluting stent (SES) implantation.
Methods: From April 2004 and March 2008, a total of 985 consecutive patients with 1304 lesions undergoing percutaneous coronary intervention only with SES implantation were analyzed. Patients and lesions were divided into tertile group: TSL per patient (PA group [13-23 mm], n=466; PB group [24-41 mm], n=164; and PC group [42-196 mm], n=355), and TSL per lesion (LA group [8-18 mm], n=508; LB group [19-28 mm], n=317; and LC group [29-125 mm], n=479). We assessed the cumulative 10-year incidence of clinically driven target-lesion revascularization (CD-TLR) and definite stent thrombosis (ST) based on TSL per patient (TSL-P) and lesion (TSL-L) groupings, and cardiac death and myocardial infarction in the TSL-P groupings.
Results: The cumulative 10-year incidence of CD-TLR for the TSL-P and TSL-L were higher in the PC and LC groups than in the other groups (19.0% vs. 17.4% vs. 28.2%, p=0.02 and 19.3% vs. 19.7% vs. 24.1%, p=0.04, respectively). No significant differences in the cumulative 10-year incidence of definite ST were observed in both TSL-P and TSL-L groups (2.2% vs. 0.79% vs. 4.0%, p=0.08 and 1.9% vs. 3.7% vs. 2.0%, p=0.61, respectively). No significant differences in the cumulative 10-year incidence of cardiac death and myocardial infarction were also observed in TSL-P groups.
Conclusions: TSL after SES implantation has significantly impact on CD-TLR rate through 10 years, but it is not associated with an increased incidence of definite ST.
Author Disclosures: T. Hiromasa: None. S. Kuramitsu: None. H. Jinnouchi: None. M. Miura: None. Y. Matsumura: None. Y. Yamaji: None. T. Domei: None. K. Yamaji: None. M. Hyodo: None. Y. Soga: None. S. Shirai: None. K. Ando: None.
- © 2016 by American Heart Association, Inc.